MARKET

NEXI

NEXI

Neximmune, Inc.
NASDAQ
5.61
+0.10
+1.81%
After Hours: 5.60 -0.01 -0.18% 19:59 03/28 EDT
OPEN
5.51
PREV CLOSE
5.51
HIGH
5.70
LOW
5.51
VOLUME
12.55K
TURNOVER
0
52 WEEK HIGH
28.69
52 WEEK LOW
1.250
MARKET CAP
7.31M
P/E (TTM)
-0.1335
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NEXI last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at NEXI last week (0311-0315)?
Weekly Report · 03/18 10:42
Weekly Report: what happened at NEXI last week (0304-0308)?
Weekly Report · 03/11 10:40
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
HighPeak Energy, Inc. Shares fell 15.3% to $13.49 on Thursday. The company reported worse-than-expected fourth-quarter revenue results. Lytus Technologies Holdings PTV. Ltd. Shares jumped 404% in the mid-day session.
Benzinga · 03/07 18:35
Rentokil Initial, Avangrid, American Eagle Outfitters among premarket gainers' pack
Rentokil Initial, Avangrid, American Eagle Outfitters among premarket gainers' pack. Lytus Technologies +210% after entering $326 billion data center market. Honest Company +33% after reporting a profit in Q4. CERo Therapeutics +625% after preclinical research supporting use of clinical candidate to treat AML patients.
Seeking Alpha · 03/07 14:09
Weekly Report: what happened at NEXI last week (0226-0301)?
Weekly Report · 03/04 10:42
Weekly Report: what happened at NEXI last week (0219-0223)?
Weekly Report · 02/26 10:52
NexImmune Has Received A Decision To Grant European Patent Number EP3970748 Titled "Nanoparticle Compositions And Methods For Immunotherapy"
Benzinga · 02/20 16:38
More
About NEXI
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML) and NEXI-002 in multiple myeloma (MM). The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company’s T cell product candidates are designed to combine the attributes of cellular with reduced potential for toxicities. It is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.

Webull offers Neximmune Inc stock information, including NASDAQ: NEXI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEXI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NEXI stock methods without spending real money on the virtual paper trading platform.